In regard to the naming guidance for biosimilars that states that each product must be given a random 4-letter suffix that is devoid of meaning, the organization encourages the FDA to reconsider.
Since the release of the Biosimilar Action Plan (BAP) last month, many industry stakeholders have offered their thoughts on the efforts outlined in the plan. Response to the release of the plan as well as strategies to spur biosimilar uptake have been largely positive, though some groups offered advice on how best to achieve this goal.
Recently, the Biologics Prescribers Collaborative (BPC) offered its take on the plan, noting that, as an organization, it “advocates for policies that promote development and approval of biosimilar medicines while maintaining the highest standards of safety and efficacy.”
The BPC supports the FDA in actions to prioritize effective communication with prescribers, patients, and payers, and continue educational efforts on biosimilars for these groups. Additionally, the BPC also encourages the FDA’s plan to develop application review templates that will not only improve the efficiency of biosimilar and interchangeable development and approval, but also enhance public information around this process.
While part of the FDA’s efforts include updating its guidance on interchangeability, the BPC had a note of caution against any modified rules that may lower the standards for interchangeability. “To further the development and designation of interchangeable biosimilar products and ensure the rigorous nature of these standards, BPC believes data required to demonstrate interchangeability should be robust and risk-based,” its comments noted.
The BPC also recommends that manufacturers be required to perform studies to determine whether alternating between a reference product and a proposed interchangeable biosimilar multiple times impacts the safety or efficacy of the drug.
In regard to the naming guidance for biosimilars that states that each product must be given a random 4-letter suffix that is devoid of meaning, the BPC encourages the FDA to reconsider, stating that instead, the suffix should be memorable.
Overall, however, the BPC was supportive of the FDA’s efforts to generate more biosimilar uptake, and applauded the FDA for listening to its stakeholders and working to optimize the regulatory framework.
“BPC looks forward to continued engagement with the FDA to support the implementation of the BAP in a way that fosters physician understanding, confidence, and uptake in this new important class of medicines,” read the comments.
CHMP Pushes 3 Biosimilars Forward, Spelling Hope for Ophthalmology, Supportive Care Markets
February 6th 2025The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended 3 biosimilars and new indications for reference biologics, moving them closer to final European approval and expanding patient access.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
BioRationality: No More Biosimilars—Just Biogenerics
February 3rd 2025Sarfaraz K. Niazi, PhD, argues that regulatory agencies should eliminate redundant clinical efficacy testing for biosimilars, recognizing them as "biogenerics" since physicochemical and in vitro biological comparisons are sufficient to ensure safety and efficacy.
FTC Releases Second Report on PBMs Meddling in Generic Drug Markets
January 19th 2025The 3 largest pharmacy benefit managers (PBMs) increased many specialty generic drugs prices by hundreds of percent, with some drugs seeing thousands of percent markups, according to the Federal Trade Commission (FTC)’s second interim report on PBM practices.
Improving Biosimilar Access Through Global Regulatory Convergence
January 15th 2025Achieving global regulatory harmonization for biosimilar vaccines and immunotherapies is essential to improving market access, reducing costs, and enhancing patient outcomes by streamlining approval processes, fostering international collaboration, and addressing regulatory disparities.